Dominic Calleja
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Dominic Calleja has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
Bright Uchenna Oparaji
Institute for Risk and Uncertainty, University of Liverpool, Liverpool, United Kingdom
3 shared publications- Nicholas Gray
University of Liverpool
3 shared publications - Alexander Wimbush
Institute for Risk and Uncertainty, University of Liverpool, Liverpool, UK
2 shared publications - Enrique Miralles-Dolz
Princeton Plasma Physics Laboratory
2 shared publications Louis Clearkin
Wirral & Liverpool University Teaching Hospitals, Birkenhead, United Kingdom
2 shared publications- Scott Ferson
University of Liverpool
2 shared publications
Latest Publications
- Open Access
- 21 October 2020
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 15 (10) , e0240775
Is “no test is better than a bad test”? Impact of diagnostic uncertainty in mass testing on the spread of COVID-19
Testing is viewed as a critical aspect of any strategy to tackle epidemics. Much of the dialogue around testing has concentrated on how countries can scale up capacity, but the uncertainty in testing has not received nearly as much attention beyond asking if a test is accurate enough to be used. Even for highly accurate tests, false positives and false negatives will accumulate as mass testing strategies are employed under pressure, and these misdiagnoses could have major implications on the ability of governments to suppress the virus. The present analysis uses a modified SIR model to understand the implication and magnitude of misdiagnosis in the context of ending lockdown measures. The results indicate that increased testing capacity alone will not provide a solution to lockdown measures. The progression of the epidemic and peak infections is shown to depend heavily on test characteristics, test targeting, and prevalence of the infection. Antibody based immunity passports are rejected as a solution to ending lockdown, as they can put the population at risk if poorly targeted. Similarly, mass screening for active viral infection may only be beneficial if it can be sufficiently well targeted, otherwise reliance on this approach for protection of the population can again put them at risk. A well targeted active viral test combined with a slow release rate is a viable strategy for continuous suppression of the virus.
- 21 October 2020
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 15 (10) , e0240775
Open AccessIs “no test is better than a bad test”? Impact of diagnostic uncertainty in mass testing on the spread of COVID-19
Testing is viewed as a critical aspect of any strategy to tackle epidemics. Much of the dialogue around testing has concentrated on how countries can scale up capacity, but the uncertainty in testing has not received nearly as much attention beyond asking if a test is accurate enough to be used. Even for highly accurate tests, false positives and false negatives will accumulate as mass testing strategies are employed under pressure, and these misdiagnoses could have major implications on the ability of governments to suppress the virus. The present analysis uses a modified SIR model to understand the implication and magnitude of misdiagnosis in the context of ending lockdown measures. The results indicate that increased testing capacity alone will not provide a solution to lockdown measures. The progression of the epidemic and peak infections is shown to depend heavily on test characteristics, test targeting, and prevalence of the infection. Antibody based immunity passports are rejected as a solution to ending lockdown, as they can put the population at risk if poorly targeted. Similarly, mass screening for active viral infection may only be beneficial if it can be sufficiently well targeted, otherwise reliance on this approach for protection of the population can again put them at risk. A well targeted active viral test combined with a slow release rate is a viable strategy for continuous suppression of the virus.
- 23 August 2020
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 59 (12) , e159
Comment on: British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis
- 23 August 2020
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 59 (12) , e159
Comment on: British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis
- Open Access
Is “no test is better than a bad test”? Impact of diagnostic uncertainty in mass testing on the spread of COVID-19
Testing is viewed as a critical aspect of any strategy to tackle epidemics. Much of the dialogue around testing has concentrated on how countries can scale up capacity, but the uncertainty in testing has not received nearly as much attention beyond asking if a test is accurate enough to be used. Even for highly accurate tests, false positives and false negatives will accumulate as mass testing strategies are employed under pressure, and these misdiagnoses could have major implications on the ability of governments to suppress the virus. The present analysis uses a modified SIR model to understand the implication and magnitude of misdiagnosis in the context of ending lockdown measures. The results indicate that increased testing capacity alone will not provide a solution to lockdown measures. The progression of the epidemic and peak infections is shown to depend heavily on test characteristics, test targeting, and prevalence of the infection. Antibody based immunity passports are rejected as a solution to ending lockdown, as they can put the population at risk if poorly targeted. Similarly, mass screening for active viral infection may only be beneficial if it can be sufficiently well targeted, otherwise reliance on this approach for protection of the population can again put them at risk. A well targeted active viral test combined with a slow release rate is a viable strategy for continuous suppression of the virus.
Open AccessIs “no test is better than a bad test”? Impact of diagnostic uncertainty in mass testing on the spread of COVID-19
Testing is viewed as a critical aspect of any strategy to tackle epidemics. Much of the dialogue around testing has concentrated on how countries can scale up capacity, but the uncertainty in testing has not received nearly as much attention beyond asking if a test is accurate enough to be used. Even for highly accurate tests, false positives and false negatives will accumulate as mass testing strategies are employed under pressure, and these misdiagnoses could have major implications on the ability of governments to suppress the virus. The present analysis uses a modified SIR model to understand the implication and magnitude of misdiagnosis in the context of ending lockdown measures. The results indicate that increased testing capacity alone will not provide a solution to lockdown measures. The progression of the epidemic and peak infections is shown to depend heavily on test characteristics, test targeting, and prevalence of the infection. Antibody based immunity passports are rejected as a solution to ending lockdown, as they can put the population at risk if poorly targeted. Similarly, mass screening for active viral infection may only be beneficial if it can be sufficiently well targeted, otherwise reliance on this approach for protection of the population can again put them at risk. A well targeted active viral test combined with a slow release rate is a viable strategy for continuous suppression of the virus.